Evidence map›Paper›PMID 36982049›Full record

ArticleInternational journal of environmental research and public health2023

A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD).

Alondra Velez-Santiago, Edwin Alvarez-Torres, Ricardo Martinez-Rodriguez, Emmanuel Candal-Rivera, Luis Muniz-Camacho, Luis Ramos-Burgos, Esther A Torres

Open access · goldFull text read
In one paragraph

Article in International journal of environmental research and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Cannabinoids and the Gastrointestinal Tract.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Alondra Velez-SantiagoDepartment of Medicine, School of Medicine, University of Puerto Rico Medical Sciences Campus, PR Medical Center, San Juan, PR 00935, USA.
Edwin Alvarez-TorresDepartment of Medicine, School of Medicine, University of Puerto Rico Medical Sciences Campus, PR Medical Center, San Juan, PR 00935, USA.
Ricardo Martinez-RodriguezDepartment of Medicine, School of Medicine, University of Puerto Rico Medical Sciences Campus, PR Medical Center, San Juan, PR 00935, USA.
Emmanuel Candal-RiveraVeterans Affairs Caribbean Health System, 10 Calle Casia, San Juan, PR 00921-3201, USA.
Luis Muniz-CamachoVeterans Affairs Caribbean Health System, 10 Calle Casia, San Juan, PR 00921-3201, USA.
Luis Ramos-BurgosMassachussetts General Hospital, 55 Fruit St., Boston, MA 02114, USA.
Esther A TorresDepartment of Medicine, School of Medicine, University of Puerto Rico Medical Sciences Campus, PR Medical Center, San Juan, PR 00935, USA.
University of Puerto Rico, Medical Sciences Campus · PRVA Caribbean Healthcare System · PRMassachusetts General Hospital · US

Funding

UPR School of Medicine Endowed Health Services Research*S21MD000242 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FRONTERA, WALTER R · 2002 to 2004
$15.0M
UPR School of Medicine Program for Research ExcellenceS21MD000138 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI JOGLAR, FRANCISCO M · 2002 to 2002
$2.9M
NIMHD NIH HHS S21 MD000138NIMHD NIH HHS S21 MD000242
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBDs) are chronic conditions of unknown cause or cure. Treatment seeks to reduce symptoms and induce and maintain remission. Many patients have turned to alternatives, such as cannabis, to alleviate living with IBD. This study reports the demographics, prevalence, and perception on cannabis use of patients attending an IBD clinic. Patients agreed to participate and completed an anonymous survey during their visit or online. Descriptive analysis, Fisher's exact test, and Wilcoxon-Mann-Whitney rank-sum test were used. One hundred and sixty-two adults (85 males, 77 with CD) completed the survey. Sixty (37%) reported use of cannabis, of which 38 (63%) used it to relieve their IBD. A value of 77% reported low to moderate knowledge about cannabis, and 15% reported little to no knowledge. Among cannabis users, 48% had discussed use with their physician, but 88% said they would feel comfortable discussing medical cannabis for IBD. Most saw improvement of their symptoms (85.7%). A considerable number of patients with IBD use medical cannabis for their disease, unknown to their physician. The study reinforces the importance that physicians understand the role of cannabis in the treatment of IBD in order to appropriately counsel patients.

Indexed as

CannabisHallucinogensInflammatory Bowel DiseasesMedical MarijuanaAdultHumansMaleSurveys and QuestionnairesHallucinogensMedical Marijuanacannabisinflammatory bowel diseasemedical marijuana

Identifiers

PMID36982049
PMCPMC10049263
OpenAlexW4324365369

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read60
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.